NIMIUM Therapeutics is a Montreal biotech focused on the development of an innovative therapeutic to treat cardiometabolic diseases (CMDs). Our research is based on glycerol-3-phosphate phosphatase (G3PP), an enzyme found to play a central role in glucose, lipid, and energy metabolism in humans. We are currently optimizing hit G3PP activators. NIMIUM has partnerships with adMare BioInnovations, and with Paraza Pharma, a leading contract research organization specialized in drug development. NIMIUM has received funding from Investissement Quebec.